Hospira is voluntarily recalling three lots of the injectable opioid medication Hydromorphone HCl because the glass vials may be broken or cracked, the Food and Drug Administration announced yesterday. Hospira has notified hospitals and others with an existing inventory of the lots subject to this recall that they should stop use and distribution of the remaining units and quarantine them immediately. See the FDA announcement for more information, including the lot numbers. Health care professionals are encouraged to report any related problems or events to the FDA's MedWatch Program. Last week, the AHA and others asked the Drug Enforcement Administration to temporarily adjust the aggregate production quotas for certain injectable opioid medications in short supply to allow other manufacturers to supply product until the shortages resolve.
 

Related News Articles

Headline
Stephanie Calcasola, R.N., chief quality officer and vice president of quality and safety at Hartford HealthCare, unpacks the programs, technology and cultural…
Headline
Wendy Kim, DNP, R.N., vice president and chief nursing officer of Henry Ford Health in Michigan, shares how the system’s virtual nursing program is reducing…
Headline
The Centers for Disease Control and Prevention announced Dec. 16 that it adopted individual-based decision-making for parents deciding whether to give the…
Headline
The Centers for Disease Control and Prevention issued an advisory Dec. 3 on an outbreak of Marburg virus in Ethiopia. The agency said a risk of spread to the U…
Headline
The AHA released a report Dec. 4 that found patient safety in hospitals and health systems across the nation continues to improve. The report, which uses data…
Headline
The AHA will host a webinar Dec. 18 at 1 p.m. ET on strategies to better protect senior leaders in hospitals. Attendees will learn ways to reduce…